Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTA) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business’s revenue was down 22.8% on a year-over-year basis. During the same period last year, the business earned ($1.33) EPS. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $5.11 on Monday. Enanta Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $17.80. The stock has a market cap of $109.01 million, a price-to-earnings ratio of -0.93 and a beta of 0.56. The firm’s 50-day moving average is $6.31 and its 200-day moving average is $10.06.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Robert W. Baird decreased their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright cut their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.64% of the stock is currently owned by corporate insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.